Matching-adjusted indirect comparisons: A new tool for timely comparative effectiveness research

Value in Health

Volumn 15, Issue 6, 2012, Pages 940-947

  Signorovitch, James E ^a   Sikirica, Vanja ^b   Erder, M Haim ^b   Xie, Jipan ^a   Lu, Mei ^a   Hodgkins, Paul S ^b   Betts, Keith A ^a   Wu, Eric Q ^a  

^a ANALYSIS GROUP   (United States)

^b SHIRE   (United States)

Author keywords

comparative effectiveness; individual patient data; matching adjusted indirect comparison

Indexed keywords

ADALIMUMAB; ATOMOXETINE; DASATINIB; ETANERCEPT; GUANFACINE; NILOTINIB; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; HEALTH CARE QUALITY; HUMAN; MATCHING ADJUSTED INDIRECT COMPARISON; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPENSITY SCORE; PSORIASIS; PUBLISHING; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84866426755     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.05.004     Document Type: Article

References (50)

1. A. Sutton, A.E. Ades, N. Cooper Use of indirect and mixed treatment comparisons for technology assessment Pharmacoeconomics 26 2008 753 767
2. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
3. D.C. Hoaglin, N. Hawkins, J.P. Jansen Conducting indirect-treatment- comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices, Part 2 Value Health 14 2011 429 437
4. J.P. Jansen, R. Fleurence, B. Devine Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices, Part 1 Value Health 14 2011 417 428
5. G.A. Wells, S.A. Sultan, L. Chen Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis 2009 Canadian Agency for Drugs and Technologies in Health Ottawa, Ontario, Canada
6. NICE Guide to the Methods of Technology Appraisal http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed May 18, 2012]
7. S. Dias, N.J. Welton, A.J. Sutton, A.E. Ades NICE DSU Technical Support Document 1: introduction to evidence synthesis for decision making http://www.nicedsu.org.uk 2011 [Accessed May 18, 2012]
8. S. Dias, N.J. Welton, A.J. Sutton, A.E. Ades NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials http://www.nicedsu.org.uk 2011 [Accessed May 18, 2012]
9. S. Dias, A.J. Sutton, N.J. Welton, A.E. Ades NICE DSU Technical Support Document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment http://www.nicedsu.org.uk 2011 [Accessed May 18, 2012]
10. S. Dias, N.J. Welton, A.J. Sutton NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. 2011 http://www.nicedsu.org.uk [Accessed May 18, 2012]
11. R. Chou, R. Fu, L. Hoyt Human, P. Korthuis Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses Lancet 368 2006 1503 1515
12. S. Greenland, H. Morgenstern Ecological bias, confounding, and effect modification Int J Epidemiol 18 1989 269 274
13. J.A. Berlin, J. Santanna, C.H. Schmid Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head Stat Med 21 2002 371 387
14. J.P. Pignon, R. Arriagada, D.C. Ihde A meta-analysis of thoracic radiotherapy for small-cell lung cancer N Engl J Med 327 1992 1618 1624
15. Homocysteine Lowering Trialists' Collaboration Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials BMJ 316 1998 894 898
16. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
17. R.A. Moore, H.J. McQuay Single-patient data metaanalysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics Pain 69 1997 287 294
18. R.M. Turner, R.Z. Omar, M. Yang A multilevel model framework for meta-analysis of clinical trials with binary outcomes Stat Med 19 2000 3417 3432
19. P.R. Rosenbaum, D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
20. K. Hirano, G. Imbens Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization Health Serv Outcomes Res Method 2 2001 259 278
21. J.E. Signorovitch, E.Q. Wu, A.P. Yu Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept Pharmacoeconomics 28 2010 935 945
22. J.E. Signorovitch, E.Q. Wu, E. Swallow Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials Clin Drug Investig 31 2011 665 674
23. Y. Iwamoto, N. Tajima, T. Kadowaki Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial Diabetes Obesity Metab 12 2010 613 622
24. Y. Iwamoto, T. Taniguchi, K. Nonaka Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Endocr J 57 2010 383 394
25. Y. Iwamoto, A. Kashiwagi, N. Yamada Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study Diabetes Obesity Metab 12 2010 700 708
26. M. Kikuchi, N. Abe, M. Kato Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus Diabetes Res Clin Pract 83 2009 233 240
27. K. Nonaka, T. Kakikawa, A. Sato Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes Diabetes Res Clin Pract 79 2008 291 298
28. W. Fakhoury, C. LeReun, D. Wright A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes Pharmacology 86 2010 44 57
29. B. Richter, E. Bandeira-Echtler, K. Bergerhoff, C.L. Lerch Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2 2008 CD006739
30. R.A. DeFronzo, A.H. Stonehouse, J. Han, M.E. Wintle Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials Diabetic Med 27 2010 309 317
31. J.H. Saurat, G. Stingl, L. Dubertret Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
32. A. Menter, S.K. Tyring, K. Gordon Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
33. C.L. Leonardi, J.L. Powers, R.T. Matheson Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
34. K.A. Papp, S. Tyring, M. Lahfa A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
35. K.B. Gordon, R.G. Langley, C. Leonardi Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606
36. J.E. Signorovitch, E.Q. Wu, K.A. Betts Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials Curr Med Res Opin 27 2011 1263 1271
37. J.E. Cortes, M. Baccarani, F. Guilhot Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 28 2010 424 430
38. G. Wei, S. Rafiyath, D. Liu First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib J Hematol Oncol 3 2010 47
39. G. Saglio, D.W. Kim, S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
40. H. Kantarjian, N.P. Shah, A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
41. J. Biederman, R.D. Melmed, A. Patel A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder Pediatrics 121 2008 e73 e84
42. F. Sallee, J. McGough, T. Wigal Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry 48 2009 155 165
43. D.K. Kelsey, C.R. Sumner, C.D. Casat Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial Pediatrics 114 2004 e1 e8
44. T. Spencer, J.H. Heiligenstein, J. Biederman Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder J Clin Psychiatry 63 2002 1140 1147
45. D. Michelson, A.J. Allen, J. Busner Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 159 2002 1896 1901
46. D. Michelson, D. Faries, J. Wernicke Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study Pediatrics 108 2001 E83
47. Intuniv package insert http://pi.shirecontent.com/PI/PDFs/Intuniv-USA- ENG.pdf [Accessed May 18, 2012]
48. Strattera package insert http://pi.lilly.com/us/strattera-pi.pdf [Accessed May 18, 2012]
49. H.C. Bucher, G.H. Guyatt, L.E. Griffith The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
50. A.M. Glenny, D.G. Altman, F. Song Indirect comparisons of competing interventions Health Technol Assess 9 2005 1 134 iii-iv